Revised Korean Society of Infectious Diseases/National Evidence-based Healthcarea Collaborating Agency Guidelines on the Treatment of Patients with COVID-19

다국어 초록 (Multilingual Abstract)

Despite the global effort to mitigate the spread, coronavirus disease 2019 (COVID-19) has become a pandemic that took more than 2 million lives. There are numerous ongoing clinical studies aiming to find treatment options and many are being published daily. Some effective treatment options, albeit of variable efficacy, have been discovered. Therefore, it is necessary to develop an evidence-based methodology, to continuously check for new evidence, and to update recommendations accordingly. Here we provide guidelines on pharmaceutical treatment for COVID-19 based on the latest evidence.

참고문헌 (Reference)

1 Kotak S, "Use of tocilizumab in COVID-19: a systematic review and meta-analysis of current evidence" 12 : e10869-, 2020

2 The COVID-19 RISK and Treatments (CORIST) Collaboration, "Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study" 82 : 38-47, 2020

3 Cheng Y, "Use of convalescent plasma therapy in SARS patients in Hong Kong" 24 : 44-46, 200

4 안진영, "Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea" 대한의학회 35 (35): e149-, 2020

5 Lian N, "Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study" 26 : 917-921, 2020

6 Hung IF, "Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial" 395 : 1695-1704, 2020

7 Rodríguez-Baño J, "Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)" 27 : 244-252, 2021

8 Arshad S, "Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19" 97 : 396-403, 2020

9 Chan KS, "Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study" 9 : 399-406, 2003

10 Ulrich RJ, "Treating COVID-19 with hydroxychloroquine (TEACH): a multicenter, double-blind randomized controlled trial in hospitalized patients" 7 : 2020

11 Choy EH, "Translating IL-6 biology into effective treatments" 16 : 335-345, 2020

12 Chilimuri S, "Tocilizumab use in patients with moderate to severe COVID-19: a retrospective cohort study" 46 : 440-446, 2021

13 Guaraldi G, "Tocilizumab in patients with severe COVID-19: a retrospective cohort study" 2 : e474-e484, 2020

14 Wang D, "Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial" 2021

15 Rosas IO, "Tocilizumab in hospitalized patients with severe Covid-19 pneumonia" 2021

16 Kewan T, "Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort study" 24 : 100418-, 2020

17 Lan SH, "Tocilizumab for severe COVID-19: a systematic review and meta-analysis" 56 : 106103-, 2020

18 Biran N, "Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study" 2 : e603-e612, 2020

19 Lewis SR, "Thomas CM, Smith AF. Pharmacological agents for adults with acute respiratory distress syndrome" 7 : CD004477-, 2019

20 World Health Organization (WHO), "Therapeutics and COVID-19: living guideline"

21 McGonagle D, "The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease" 19 : 102537-, 2020

22 Lund LH, "The registry of the international society for heart and lung transplantation: thirty-fourth adult heart transplantation report-2017; focus theme: allograft ischemic time" 36 : 1037-1046, 2017

23 Eslami G, "The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19" 75 : 3366-3372, 2020

24 Chrousos GP, "The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation" 332 : 1351-1362, 1995

25 Yuan J, "The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients" 69 : 599-606, 2020

26 Wang X, "The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro" 6 : 28-, 2020

27 Krafft P, "The acute respiratory distress syndrome: definitions, severity and clinical outcome. An analysis of 101 clinical investigations" 22 : 519-529, 1996

28 Ströher U, "Severe acute respiratory syndrome-related coronavirus is inhibited by interferon- alpha" 189 : 1164-1167, 2004

29 Ruiz-Irastorza G, "Second week methyl-prednisolone pulses improve prognosis in patients with severe coronavirus disease 2019 pneumonia: an observational comparative study using routine care data" 15 : e0239401-, 2020

30 Arabi YM, "Saudi critical care trial group. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome" 197 : 757-767, 2018

31 Satlin MJ, "Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease" 15 : e0236778-, 2020

32 Joyner MJ, "Safety update: COVID-19convalescent plasma in 20,000 hospitalized patients" 95 : 1888-1897, 2020

33 Monk PD, "Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial" 9 : 196-206, 2021

34 Huang HD, "Safety and effectiveness of hydroxychloroquine and azithromycin combination therapy for treatment of hospitalized patients with COVID-19: a propensity-matched study" 9 : 523-534, 2020

35 Stockman LJ, "SARS: systematic review of treatment effects" 3 : e343-, 2006

36 Chu CM, "Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings" 59 : 252-256, 2004

37 Roche, "Roche's phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia"

38 Szente Fonseca SN, "Risk of hospitalization for Covid-19 outpatients treated with various drug regimens in Brazil: Comparative analysis" 38 : 101906-, 2020

39 Campbell L, "Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials" 50 : 552-562, 2011

40 Mikami T, "Risk factors for mortality in patients with COVID-19 in New York city" 36 : 17-26, 2021

41 Tong S, "Ribavirin therapy for severe COVID-19: a retrospective cohort study" 56 : 106114-, 2020

42 Morgenstern B, "Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines" 326 : 905-908, 2005

43 Weniger H, "Review of side effects and toxicity of chloroquine" WHO 1979

44 WHO Solidarity Trial Consortium, "Repurposed antiviral drugs for Covid-19 - Interim WHO solidarity trial results" 384 : 497-511, 2021

45 Choy KT, "Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2replication in vitro" 178 : 104786-, 2020

46 Wang Y, "Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial" 395 : 1569-1578, 2020

47 Wang M, "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro" 30 : 269-271, 2020

48 Lian XJ, "Reevaluating the role of corticosteroids in septic shock: an updated meta-analysis of randomized controlled trials" 2019 : 3175047-, 2019

49 Arshad U, "Prioritization of anti-SARS-Cov-2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics" 108 : 775-790, 2020

50 Sciascia S, "Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19" 38 : 529-532, 2020

51 Meduri GU, "Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time" 107 : 1062-1073, 1995

52 Magagnoli J, "Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19" 1 : 114-127.e3, 2020

53 Montesarchio V, "Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy" 8 : e001089-, 2020

54 National Institutes of Health (NIH), "Ongoing clinical trials for interferon and COVI-19"

55 Kocayiğit H, "Observational study of the effects of favipiravir vs lopinavir/ritonavir on clinical outcomes in critically Ill patients with COVID-19" 46 : 454-459, 2021

56 Geleris J, "Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19" 382 : 2411-2418, 2020

57 . Huang YQ, "No statistically apparent difference in antiviral effectiveness observed among ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate coronavirus disease 2019:results of a randomized, open-labeled prospective study" 11 : 1071-, 2020

58 Molina JM, "No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection" 50 : 384-, 2020

59 Faíco-Filho KS, "No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in non-critical hospitalized patients with COVID-19" 51 : 1765-1769, 2020

60 Berardicurti O, "Mortality in tocilizumab-treated patients with COVID-19: a systematic review and meta-analysis" 38 : 1247-1254, 2020

61 Jeronimo CMP, "Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial" 2020

62 Kanoh S, "Mechanisms of action and clinical application of macrolides as immunomodulatory medications" 23 : 590-615, 2010

63 Catteau L, "Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants" 56 : 106144-, 2020

64 Yu B, "Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19" 63 : 1515-1521, 2020

65 Ji-Won Kim, "Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019" 대한내과학회 36 : S253-S263, 2021

66 RECOVERY Collaborative Group, "Lopinavir-ritonavir in patients admitted to hospital with COVID-19(RECOVERY): a randomised, controlled, open-label, platform trial" 396 : 1345-1352, 2020

67 Sakoulas G, "Intravenous immunoglobulin (IVIG) significantly reduces respiratory morbidity in COVID-19pneumonia: a prospective randomized trial" 2020

68 Akira S, "Interleukin-6 in biology and medicine" 54 : 1-78, 1993

69 Coomes EA, "Interleukin-6 in Covid-19: a systematic review and meta-analysis" 30 : 1-9, 2020

70 Cavalli G, "Interleukin-1 blockade with highdose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study" 2 : e325-e331, 2020

71 Clementi N, "Interferon-β-1a inhibition of severe acute respiratory syndrome-coronavirus 2 in vitro when administered after virus infection" 222 : 722-725, 2020

72 Food and Drug Administration (FDA), "Interferon alpha-2b (Intron® A)"

73 Food and Drug Administration (FDA), "Interferon alpha-2b (Intron® A)"

74 Tan EL, "Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs" 10 : 581-586, 2004

75 Meduri GU, "Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome" 108 : 1303-1314, 1995

76 Zhang Q, "Inborn errors of type I IFN immunity in patients with life-threatening COVID-19" 370 : eabd4570-, 2020

77 Andreani J, "In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2shows synergistic effect" 145 : 104228-, 2020

78 Chen F, "In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds" 31 : 69-75, 2004

79 Keyaerts E, "In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine" 323 : 264-268, 2004

80 Yao X, "In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)" 71 : 732-739, 2020

81 Ingraham NE, "Immunomodulation in COVID-19" 8 : 544-546, 2020

82 Liu J, "Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro" 6 : 16-, 2020

83 Cavalcanti AB, "Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19" 383 : 2041-2052, 2020

84 Karolyi M, "Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients : Results from a real-life patient cohort" 2020 : 1-8, 2020

85 Kalligeros M, "Hydroxychloroquine use in hospitalised patients with COVID-19: an observational matched cohort study" 22 : 842-844, 2020

86 Abd-Elsalam S, "Hydroxychloroquine in the treatment of COVID-19: a multicenter randomized controlled study" 103 : 1635-1639, 2020

87 Tang W, "Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial" 369 : 2020

88 Skipper CP, "Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized Trial" 173 : 623-631, 2020

89 Annie FH, "Hydroxychloroquine in hospitalized patients with COVID-19: real-world experience assessing mortality" 4 : 1072-1081, 2020

90 Mitjà O, "Hydroxychloroquine for early treatment of adults with mild Covid-19: a randomized-controlled trial" 2020

91 Gautret P, "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial" 56 : 105949-, 2020

92 Franchimont D, "Glucocorticoids and inflammation revisited:the state of the art. NIH clinical staff conference" 10 : 247-260, 2003

93 Schünemann H, "GRADE handbook"

94 Guyatt G, "GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes" 66 : 151-157, 2013

95 Dörnemann J, "First Newborn Baby to Receive Experimental Therapies Survives Ebola Virus Disease" 215 : 171-174, 2017

96 Shiraki K, "Favipiravir, an anti-influenza drug against life-threatening RNA virus infections" 209 : 107512-, 2020

97 Chen C, "Favipiravir versus arbidol for COVID-19: a randomized clinical trial" 2020

98 Furuta Y, "Favipiravir (T-705), a novel viral RNA polymerase inhibitor" 100 : 446-454, 2013

99 Cai Q, "Experimental treatment with favipiravir for COVID-19: an open-label control study" 6 : 1192-1198, 2020

100 Abbaspour Kasgari H, "Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial" 75 : 3373-3378, 2020

101 Barnard DL, "Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice" 17 : 275-284, 2006

102 Sahr F, "Evaluation of convalescent whole blood for treating ebola virus disease in freetown, Sierra Leone" 74 : 302-309, 2017

103 "Errors"

104 Esper RB, "Empirical treatment with hydroxychloroquine and azithromycin for suspected cases of COVID-19 followed-up by telemedicine"

105 Yethindra V, "Efficacy of umifenovir in the treatment of mild and moderate COVID-19 patients" 11 : 506-509, 2020

106 Stone JH, "Efficacy of tocilizumab in patients hospitalized with Covid-19" 383 : 2333-2344, 2020

107 Aziz M, "Efficacy of tocilizumab in COVID-19: a systematic review and meta-analysis" 93 : 1620-1630, 2021

108 Fang J, "Efficacy of early combination therapy with lianhuaqingwen and arbidol in moderate and severe COVID-19 patients: a retrospective cohort study" 11 : 560209-, 2020

109 Majmundar M, "Efficacy of corticosteroids in non-intensive care unit patients with COVID-19 pneumonia from the New York Metropolitan region" 15 : e0238827-, 2020

110 Bartoletti M, "Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study" 27 : 105-111, 2021

111 Li Q, "Efficacy evaluation of early, low-dose, short-term corticosteroids in adults hospitalized with non-severe COVID-19 pneumonia: a retrospective cohort study" 9 : 823-836, 2020

112 Campochiaro C, "Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study" 76 : 43-49, 2020

113 Tleyjeh IM, "Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis" 27 : 215-227, 2021

114 Chen L, "Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study" 2020

115 Li Y, "Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial" 1 : 105-113.e4, 2020

116 Martínez-Sanz J, "Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study" 27 : 238-243, 2021

117 Hermine O, "Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial" 181 : 32-40, 2021

118 Salvarani C, "Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial" 181 : 24-31, 2021

119 Spinner CD, "Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: A randomized clinical trial" 324 : 1048-1057, 2020

120 RECOVERY Collaborative Group, "Effect of hydroxychloroquine in hospitalized patients with Covid-19" 383 : 2030-2040, 2020

121 Dequin PF, "Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients With COVID-19: a randomized clinical trial" 324 : 1298-1306, 2020

122 Tomazini BM, "Effect of dexamethasone on days alive and ventilatorfree in patients with moderate or severe acute respiratory distress syndrome and COVID-19: The CoDEX randomized clinical trial" 324 : 1307-1316, 2020

123 Li L, "Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial" 324 : 460-470, 2020

124 Self WH, "Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial" 324 : 2165-2176, 2020

125 De Rossi N, "Early use of low dose tocilizumab in patients with COVID-19: a retrospective cohort study with a complete follow-up" 25 : 100459-, 2020

126 Risch HA, "Early outpatient treatment of symptomatic, high-risk COVID-19 patients that should be ramped-up immediately as key to the pandemic crisis" 189 : 1218-1226, 2020

127 Langer-Gould A, "Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab" 99 : 291-297, 2020

128 Cauchois R, "Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19" 117 : 18951-18953, 2020

129 Qin C, "Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China" 71 : 762-768, 2020

130 Villar J, "Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial" 8 : 267-276, 2020

131 ECOVERY Collaborative Group, "Dexamethasone in hospitalized patients with Covid-19" 384 : 693-704, 2021

132 이유경, "Developing a Scoring Guide for the Appraisal of Guidelines for Research and Evaluation II Instrument in Korea: A Modified Delphi Consensus Process" 대한의학회 28 (28): 190-194, 2013

133 Biot C, "Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities" 49 : 2845-2849, 2006

134 Zhang C, "Cytokine release syndrome in severe COVID-19: interleukin-6receptor antagonist tocilizumab may be the key to reduce mortality" 55 : 105954-, 2020

135 Rochwerg B, "Corticosteroids in sepsis: an updated systematic review and meta-analysis" 46 : 1411-1420, 2018

136 Lamontagne F, "Corticosteroid therapy for sepsis: a clinical practice guideline" 362 : k3284-, 2018

137 Gharebaghi N, "Correction to: The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial" 20 : 895-, 2020

138 Agarwal A, "Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)" 371 : m3939-, 2020

139 Avendaño-Solà C, "Convalescent plasma for COVID-19: a multicenter, randomized clinical trial"

140 Gharbharan A, "Convalescent plasma for COVID-19. A randomized clinical trial"

141 Bonny A, "Conflicting evidence on the efficacy of hydroxychloroquine and azithromycin as the early treatment of COVID-19. Comment on “Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France”" 37 : 101861-, 2020

142 Paccoud O, "Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe Covid-19 in a French university hospital" 2020

143 Lecronier M, "Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2pneumonia: an opportunistic retrospective analysis" 24 : 418-, 2020

144 Sheahan TP, "Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV" 11 : 222-, 2020

145 Narain S, "Comparative survival analysis of immunomodulatory therapy for coronavirus disease 2019 cytokine storm" 159 : 933-948, 2021

146 Danesi R, "Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg" 51 : 939-945, 2003

147 National Institutes of Health (NIH), "Clinical spectrum of SARS-CoV-2 infection"

148 Ruan Q, "Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China" 46 : 846-848, 2020

149 World Health Organization (WHO), "Clinical management of severe acute respiratory infection (SARI)when COVID-19 disease is suspected: interim guidance, 13 March 2020" WHO 2020

150 Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China" 395 : 497-506, 2020

151 Gao W, "Clinical features and efficacy of antiviral drug, Arbidol in 220 nonemergency COVID-19 patients from East-West-Lake Shelter Hospital in Wuhan: a retrospective case series" 17 : 162-, 2020

152 Shao Z, "Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID-19: a multicenter retrospective cohort study" 9 : e1192-, 2020

153 Mahévas M, "Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data" 369 : m1844-, 2020

154 Gautret P, "Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study" 34 : 101663-, 2020

155 Joo Eun-Jeong, "Clinical and Virologic Effectiveness of Remdesivir Treatment for Severe Coronavirus Disease 2019 (COVID-19) in Korea: a Nationwide Multicenter Retrospective Cohort Study" 대한의학회 36 (36): e83-, 2021

156 Lou Y, "Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial" 157 : 105631-, 2021

157 Vincent MJ, "Chloroquine is a potent inhibitor of SARS coronavirus infection and spread" 2 : 69-, 2005

158 Chan JF, "Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus" 67 : 606-616, 2013

159 Sheahan TP, "Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses" 9 : 2017

160 Brown AJ, "Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase" 169 : 104541-, 2019

161 Shirley M, "Baloxavir marboxil: a review in acute uncomplicated influenza" 80 : 1109-1118, 2020

162 Parnham MJ, "Azithromycin:mechanisms of action and their relevance for clinical applications" 143 : 225-245, 2014

163 Tran DH, "Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus infection by interfering with virus internalization process" 72 : 759-768, 2019

164 Iannetta M, "Azithromycin shows anti-Zika virus activity in human glial cells" 61 : e01152-e01117, 2017

165 Li C, "Azithromycin protects against Zika virus infection by upregulating virus-induced type I and III interferon responses" 63 : E00394-E00319, 2019

166 Furtado RHM, "Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial" 396 : 959-967, 2020

167 Guérin V, "Azithromycin and hydroxychloroquine accelerate recovery of outpatients with mild/moderate COVID-19" 18 : 45-55, 2020

168 Bastard P, "Autoantibodies against type I IFNs in patients with life-threatening COVID-19" 370 : eabd4585-, 2020

169 Rosenberg ES, "Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state" 323 : 2493-2502, 2020

170 Gupta S, "Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19" 181 : 41-51, 2021

171 WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, "Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis" 324 : 1330-1341, 2020

172 Zhu Z, "Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19" 81 : e21-e23, 2020

173 Deng L, "Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: a retrospective cohort study" 81 : e1-e5, 2020

174 Blaising J, "Arbidol as a broad-spectrum antiviral: an update" 107 : 84-94, 2014

175 McChesney EW, "Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate" 75 : 11-18, 1983

176 Huet T, "Anakinra for severe forms of COVID-19: a cohort study" 2 : e393-e400, 2020

177 Guo Y, "Adverse effects of immunoglobulin therapy" 9 : 1299-, 2018

178 Boregowda U, "Addition of tocilizumab to the standard of care reduces mortality in severe COVID-19: a systematic review and meta-analysis" 7 : 586221-, 2020

179 Ivashchenko AA, "AVIFAVIR for treatment of patients with moderate COVID-19: interim results of a phase II/III multicenter randomized clinical trial" 2020

180 Beigel JH, "ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 - Final Report" 383 : 1813-1826, 2020

181 Chen W, "A study on clinical effect of Arbidol combined with adjuvant therapy on COVID-19" 92 : 2702-2708, 2020

182 Mo Y, "A review of treatment modalities for Middle East respiratory syndrome" 71 : 3340-3350, 2016

183 Simonovich VA, "A randomized trial of convalescent plasma in Covid-19 severe pneumonia" 384 : 619-629, 2021

184 Davoudi-Monfared E, "A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19" 64 : e01061-e01020, 2020

185 Doi Y, "A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19" 64 : e01897-e01820, 2020

186 Lyngbakken MN, "A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics" 11 : 5284-, 2020

187 Chen J, "A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19" 49 : 215-219, 2020

188 Chen CP, "A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19)" 15 : e0242763-, 2020

189 Cao B, "A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19" 382 : 1787-1799, 2020

190 Mulangu S, "A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics" 381 : 2293-2303, 2019